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Sertraline and Phenytoin Drug Interaction in a Geriatric Patient 
Abstract 
This report presents the case of a 78-year-old man residing in a nursing home who presented with a 
2-month history of increasing lethargy and confusion. These symptoms coincided with the initiation of 
sertraline in the patient. Among other medications, he was also taking phenytoin. The medical team 
concluded that the cause of the patient’s lethargy and confusion was a drug interaction between 
sertraline and phenytoin. Phenytoin was held, while the sertraline was slowly tapered to discontinuation. 
The patient’s symptoms resolved soon thereafter. Future research is needed to better guide clinicians in 
appropriate selection, dosing, and monitoring of selective serotonin reuptake inhibitors with concomitant 
phenytoin use. 
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CASE REPORT
Sertraline and Phenytoin Drug Interaction in 
a Geriatric Patient
Kobi T Nathan, PharmD, MEd, BCGP1 • Heather A Hopkins Gil, MD2 • Stefanie E DiLoreto, PharmD1 
Nhon A Ta, PharmD1 • Thomas V Caprio, MD, MPH, MSHPE, CMD, HMDC, FACP, AGSF3
Depression affects approximately 16% of patients who are older than 65 years of age.1 Various nonpharmacologic and pharmacologic treatment options are available for the treatment of depression. Notably, second-
generation antidepressants, which include selective serotonin reuptake inhibi-
tors (SSRIs), serotonin and norepinephrine reuptake inhibitors, and other 
agents, have been the standard treatment option for depression given their 
efficacy, tolerability, and safety profile.2
However, clinically significant drug-drug interactions between SSRIs 
and other pharmaceutical agents have been well documented. All SSRIs are 
hepatically metabolized via the cytochrome P450 (CYP) enzyme pathway 
and have inhibitory effects on these enzymes. When these agents are taken 
concurrently with other agents that are substrates of CYP isoenzymes, sig-
nificant drug interactions can occur.2-4 This case report outlines a poten-
tial clinically significant drug interaction in a nursing home (NH) resident 
who was receiving sertraline, an inhibitor of the isoenzymes CYP2C19, 
CYP2C9, and CYP2D6,5-7 at the same time as phenytoin, a substrate of the 
isoenzyme CYP2C9.
Case Report
The case is a 78-year-old man who was residing in a NH, was deaf, and 
weighed 179.9 lb. Pertinent medical history was notable for osteoporosis, 
hypertension, coronary artery disease, depression, frequent falls, mild vas-
cular dementia, hypothyroidism, hidradenitis suppurativa, and remote his-
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Abstract: This report presents the case of a 78-year-old man residing in a nurs-
ing home who presented with a 2-month history of increasing lethargy and con-
fusion. These symptoms coincided with the initiation of sertraline in the patient. 
Among other medications, he was also taking phenytoin. The medical team con-
cluded that the cause of the patient’s lethargy and confusion was a drug interac-
tion between sertraline and phenytoin. Phenytoin was held, while the sertraline 
was slowly tapered to discontinuation. The patient’s symptoms resolved soon 
thereafter. Future research is needed to better guide clinicians in appropriate se-
lection, dosing, and monitoring of selective serotonin reuptake inhibitors with 
concomitant phenytoin use.
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tory of seizures (he had had no seizures for more than 40 
years). He had no history of alcohol or substance use. His 
was taking levothyroxine, ergocalciferol, docusate sodium, 
atorvastatin, doxycycline (hidradenitis suppurativa), aspi-
rin, and phenytoin, all of which had been at stable dosing. 
The phenytoin dose, at 100 mg by mouth 4 times daily, 
had been unchanged for the past 5 years. He had no aller-
gies to medications.
In January 2016, he had reported increased depression 
symptoms to NH staff, specifically to the nursing assistants 
and to the medical provider treating him. At that time, his 
medication was changed from citalopram 20 mg by mouth 
daily to sertraline 100 mg by mouth daily. 
In March 2016, he reported symptoms of lethargy and 
confusion of unclear etiology since January to NH staff. 
Also at this time, his friends reported to NH staff that he 
was increasingly withdrawn, not engaging in conversation, 
lethargic, and delayed in responses. Examination was nota-
ble for slow responses to questions and commands. The pa-
tient had no nystagmus or tremors upon exam. Laboratory 
values showed stable renal function with creatinine of 0.5 
mg/dL, albumin level of 3.1 g/dL, normal liver function 
tests, and normal thyroid function tests. During the course 
of his confusion, he was treated for urinary tract infections 
without improvement in his cognitive function.
Psychiatry service was consulted and recommended 
tapering sertraline with intent to discontinue this medi-
cation. Free phenytoin level was measured to be 4.9 μg/
mL at initiation of sertraline taper. Archived health record 
data from 2015 was consulted for previous phenytoin levels 
and showed that the patient’s free and total phenytoin lev-
els were not elevated prior to sertraline initiation (0.5 μg/
mL and 3.8 μg/mL, respectively) (Table 1). Phenytoin was 
discontinued, and levels decreased back to his previous nor-
mal values. After tapering, sertraline was also discontinued. 
Neurology was consulted and recommended monitoring 
for seizure recurrence before introducing another antiepi-
leptic medication. His cognitive status returned to his base-
line 2 months prior. 
Discussion
In this case, the medical team concluded that the cause of 
the patient’s lethargy and confusion was a drug interaction 
between sertraline and phenytoin. The patient’s symptoms 
resolved soon after phenytoin was held and sertraline was 
slowly tapered to discontinuation.
Sertraline selectively and potently inhibits neuronal se-
rotonin reuptake while having no effect on adrenergic, cho-
linergic, γ-aminobutyric acid, dopaminergic, histaminergic, 
or benzodiazepine receptors.8 The agent is primarily metab-
olized via N-demethylation to N-desmethylsertraline, a less 
active metabolite. Multiple CYP isoenzymes participate in 
the demethylation pathway, including CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4.3,5,9 Some studies suggest that ser-
traline displays fewer clinically significant drug interactions 
compared to its other counterparts in the SSRI family.10 
However, it is notable that interpatient variability in the 
activity of CYP isoenzymes does exist and may account for 
overt drug interactions in some patients, necessitating the 
need for dose adjustment or cessation of the agent.
Phenytoin’s mechanism of action seems to be centered on 
the motor cortex, and it is postulated that the spread of seizure 
activity is inhibited at this location.11 As with all antiepileptic 
agents, there is wide interpatient variability with regard to op-
timum phenytoin dosing requirements, and treatment must 
be individualized. Sustained low plasma levels may suggest 
nonadherence to medication therapy or hypermetabolization 
of phenytoin. Sustained high plasma levels may indicate ge-
netic polymorphism pertaining to CYP2C9 and CYP2C19 
alleles, or drug-drug interactions. 
Table 1. Trend in Phenytoin Laboratory Values
10/7/15 11/9/15a 3/4/16b 3/5/16c 3/6/16d 3/7/16 3/9/16 3/14/16e
Total phenytoin (μg/mL) 3.8 Not 
ordered
Not 
ordered
32.7 25.5 19.9 11.7 < 1.5
Free phenytoin (μg/mL) 0.5 0.8 4.9 4.2 3.8 Not 
ordered
1.6 Not 
ordered
aPatient’s baseline free phenytoin levels before start of sertraline usually < 1.0 μg/mL, based on 2015 health record data.
bSertraline 100 mg daily was initiated in January 4, 2016, then tapered beginning March 1, 2016.
cPhenytoin held, stat levels ordered.
dSomnolence and lethargy resolving.
eMedical team to assess if phenytoin still needed; lorazepam for rescue ordered.
altc0817CR_Nathan.indd   47 10/5/17   9:04 AM
48   Annals of Long-Term Care® • September/October 2017 www.annalsoflongtermcare.com
Sertraline and Phenytoin Drug Interaction
Phenytoin is also highly protein bound (90%-95%), and 
this pharmacokinetic parameter is of paramount impor-
tance when planning and administering a medically appro-
priate pharmaceutical care plan for geriatric patients, many 
of whom are frail, lack body mass, or have hypoalbumin-
emia due to comorbidities and/or general clinical status. 
Notably, clearance of phenytoin decreases with increasing 
age. Patients older than 70 years of age have 20% less drug 
clearance compared with patients 20 to 30 years of age.11 In 
such patients, it would be prudent to obtain free phenytoin 
levels, since total phenytoin levels may not reflect accurately 
on the clinical status of the patient.
Since phenytoin is a substrate of CYP2C9 and CY-
P2C19, its metabolism may be inhibited by sertraline when 
both agents are used concurrently.10,12 Haselberger and col-
leagues discuss two case reports in which they observed el-
evated phenytoin levels in patients who were administered 
sertraline and phenytoin.13 In both cases, phenytoin plasma 
concentrations decreased when sertraline was discontinued, 
and the patients were discharged with no further complica-
tions. In our case report, the patient showed a similar re-
duction in phenytoin plasma concentration when sertraline 
was removed from his regimen. Although he did not exhibit 
signs of phenytoin toxicity, there was concern for a clinically 
significant drug interaction through observation of his in-
creasing lethargy and delay in processing response. 
Notably, phenytoin’s nonlinear pharmacokinetics and 
narrow therapeutic index added another layer of salience 
to the medical team’s assessment of his clinical status. To 
further add relevance to the possibility that our patient’s 
somnolence and delayed responses was secondary to the ini-
tiation of sertraline, the Drug Interaction Probability Scale 
(DIPS) was used.14 The DIPS assesses the probability of a 
causal relationship between a potential drug interaction and 
an adverse event. The score for our patient was a “6,” sug-
gesting that the likelihood of the drug interaction was prob-
able between the two drugs. Additionally, it is worth noting 
that the patient’s mood and psychomotor slowing improved 
with discontinuation of his antidepressant. This indicates 
that his symptoms were related to phenytoin levels rather 
than depression symptoms. 
It is recommended that providers pay particular attention 
to the possibility of clinically relevant drug interactions, es-
pecially when prescribing SSRIs in combination with other 
agents that are metabolized by the CYP2C subfamily of isoen-
zymes. Of note, initial and periodic monitoring of phenytoin 
plasma levels is warranted, combined with appropriate clinical 
and neurological assessment for phenytoin toxicity.
This case also highlights the need to review indications 
for antiepileptic medications in older adults. If a patient has 
been seizure free for years, coordinating dose reduction or 
discontinuation of an antiepileptic with the neurology team 
may help reduce unnecessary side effects and polypharmacy 
in older adults.  
Conclusion
This case report suggests that a clinically significant drug 
interaction may exist between phenytoin and sertraline in 
some patients, especially if they are at risk for such events 
due to poor clinical status or a genetic predisposition. 
Hence, providers are encouraged to observe their patients 
for neurological and clinical changes. Phenytoin plasma 
levels should be closely monitored at initiation of SSRIs 
and periodically during treatment. Apart from a few docu-
mented case studies, there is a paucity of data elucidating 
this clinically significant drug interaction. Future research 
is warranted to investigate the relationship between specific 
doses of each agent and the onset of symptoms in a more 
diverse patient sampling. Clinicians will then be able to ap-
ply this knowledge to aid them in the proper selection and 
dosing of SSRIs while monitoring for drug interactions and 
signs of toxicity. u
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